Related by context. All words. (Click for frequent words.) 62 BRIM3 60 BRIM2 60 HCV RESPOND 2 60 intradialytic hypotension IDH 60 teriflunomide 59 PRIMO CABG 59 MERLIN TIMI 59 Phase 2a clinical 58 pharmacokinetic PK 58 Phase 2a 58 huC# DM4 58 multicenter Phase 58 trastuzumab emtansine T DM1 58 evaluating tivozanib 58 phase IIa 58 bosentan 58 GetGoal Phase III 58 INCB# [001] 57 IIa clinical trial 57 HCV SPRINT 57 Alocrest 57 evaluating mipomersen 57 refractory gout 57 trastuzumab DM1 T DM1 57 secondary efficacy endpoints 57 ILLUMINATE 57 multicenter randomized Phase 57 formal pharmacokinetic PK 57 AVADO 57 HER2 positive metastatic breast 57 SVR# 56 alvespimycin 56 phase IIa clinical 56 telaprevir dosing 56 R#/MEM # 56 phase IIb clinical 56 Prostate AdenoCarcinoma Treatment 56 placebo controlled Phase 56 AVOREN 56 Phase 2a trial 56 ASA# 56 Phase Ib study 56 viral kinetic 56 Phase IIa clinical 56 ACTEMRA TM 56 phase IIb 56 Randomized Phase 56 Ocrelizumab 56 randomized Phase III 56 IMPACT IMmunotherapy 56 Traficet EN 56 Phase Ib clinical 56 virus HCV protease inhibitor 56 PRE SURGE 56 Phase 2b clinical 55 elagolix 55 multicenter placebo controlled 55 Azedra 55 CR# vcMMAE 55 Ophena TM 55 MDV# 55 SABCS 55 dose escalation Phase 55 Androxal TM 55 Targretin 55 axitinib 55 Phase IIB 55 Sym# 55 pharmacokinetic PK study 55 NO# [002] 55 efficacy endpoint 55 SPIRIT FIRST 55 EDEMA3 55 Aurexis 55 NLX P# 55 NASDAQ CLDX 55 INCB# [002] 55 OPT CHF 55 enzastaurin 55 TRANSFORMS 55 bepotastine besilate nasal spray 55 ORAL Sync 55 confirmatory clinical 55 TEMSO 55 Phase 1b 55 glufosfamide 55 riociguat 55 AVN# Phase 54 ongoing Phase 1b 54 Nasdaq NYMX 54 active comparator 54 Elagolix 54 Randomized Double blind 54 TASKi2 54 Phase III ALLEGRO 54 pomalidomide 54 ENDEAVOR III 54 evaluating Actimmune 54 palifosfamide Zymafos TM 54 Phase III placebo controlled 54 avosentan 54 EOquin TM phase 54 ANCHOR trial 54 PEG SN# 54 Aflibercept 54 Phase IIa trial 54 GVAX AML 54 ABSORB trial 54 Phase 2b study 54 GOUT 54 PRIMO CABG2 54 elotuzumab 54 XL# SAR# 54 ACR# responses 54 docetaxel chemotherapy 54 GALNS 54 EDEMA3 trial 54 TELCYTA 54 BCX# 54 metastatic HRPC 54 IMPACT DCM 54 ToGA 54 Phase 1b clinical trials 54 phase IIb study 54 Xanafide 54 Phase 1a clinical 54 placebo controlled clinical 54 Initiated Phase 54 BRAF V#E mutation 54 BIBW 54 LUX Lung 54 oral ridaforolimus 54 unique alkylating agent 54 Phase IIb trials 54 PCI ExTRACT TIMI 54 phase 2a 54 CYT# 54 ELACYT 54 cannabinor 54 Pharmacokinetic PK 54 Carfilzomib 54 ganetespib 53 azficel T 53 castration resistant prostate cancer 53 SPIRIT III 53 IMA# 53 Phase Ib II 53 PRECiSE 53 PSMA ADC 53 Randomized Phase II 53 HGS ETR1 53 Proellex TM 53 registrational trial 53 Azedra TM 53 R# #mg BID 53 CLARITY study 53 Summarized consolidated 53 Quinamed 53 pharmacokinetic characteristics 53 Bezielle 53 Dapagliflozin 53 HuMax EGFr 53 tesmilifene 53 HGS ETR2 53 NASDAQ ARRY 53 randomized controlled multicenter 53 Phase IIb clinical 53 MEND CABG 53 oral prodrug 53 PXD# 53 JANUVIA 53 metastatic castration resistant 53 multicentre randomized 53 eltrombopag 53 Phase 2b monotherapy 53 relapsed MM 53 Pivotal Phase III 53 REVIVE TA 53 SUCCEED trial 53 Phase IIIb clinical 53 dose cohorts 53 Topline Results 53 enoximone 53 virologic response 53 Phenoptin 53 drug pipeline TAFA# 53 randomized controlled Phase 53 diabetic neuropathic pain 53 Androxal 53 refractory multiple myeloma 53 pivotal Phase 53 lintuzumab 53 EDEMA4 53 angiographic outcomes 53 BLOOM Behavioral modification 52 CoFactor 52 iniparib 52 SYMMETRY trial 52 Pharmacokinetic parameters 52 non metastatic osteosarcoma 52 dose escalation trial 52 EOquin TM 52 plus dexamethasone 52 pharmacokinetics PK 52 dosing cohorts 52 RECORD1 52 label multicenter Phase 52 RSD# oral 52 phase Ib 52 MERIT ES 52 oral sapacitabine 52 ACTEMRA 52 PRTX 52 assessing T DM1 52 YONDELIS 52 Phase Ia 52 RSD# IV 52 crizotinib PF # 52 COMFORT II 52 velafermin 52 Phase 2b trial 52 IMC A# 52 low dose cytarabine 52 CUSTOM III 52 BAY #-# 52 CINQUIL 52 Phase 1b trial 52 Brentuximab Vedotin SGN 52 CHAMPION PCI 52 dose escalation clinical 52 multicenter randomized placebo controlled 52 PEG PAL 52 prospective multicentre 52 forodesine 52 RG# [001] 52 ocrelizumab 52 Phase Ib 52 Phase #/#a 52 PreCISe 52 ARIKACE 52 Glufosfamide 52 Phase III ADT 52 Cervista HPV HR 52 placebo controlled multicenter 52 dependent kinase inhibitor 52 elacytarabine 52 DASISION 52 HORIZONS AMI trial 52 dirucotide 52 KRAS status 52 TBC# 52 blinded randomized placebo controlled 52 Phase 1a 52 Rebif ® 52 MAGE A3 ASCI 52 exploratory endpoints 52 Sapacitabine 52 DURATION 52 PERSEUS 52 UPLYSO 52 oral rivaroxaban 52 Significant assay 52 Imprime PGG 52 NEO3 52 SuperMedia specializes 52 OncoVEX GM CSF 52 adecatumumab 52 randomized Phase 2b 51 pertuzumab 51 Tovaxin Phase IIb 51 MacroChem actual 51 MGCD# [001] 51 tolerability profile 51 Pharmacokinetic 51 NAbs 51 Atiprimod 51 Phase IIb randomized 51 telaprevir dosed 51 phase IIIb 51 Amrubicin 51 Cytokinetics Incorporated NASDAQ CYTK 51 sustained virologic response 51 sorafenib Nexavar ® 51 Phase Ib clinical trials 51 evaluating Prochymal 51 nalbuphine ER 51 Pivotal Phase 51 evaluating REVLIMID 51 novel VDA molecule 51 multiple ascending dose 51 Phase III VISTA 51 web site http:/www.nasd-law.com/documents/classvrIcy Cape 51 initiate Phase 1b 51 zotarolimus 51 XL# [003] 51 placebo controlled clinical trials 51 alvimopan 51 afatinib 51 NGX# 51 Oral Fingolimod 51 ACUITY trial 51 tanespimycin 51 efficacy endpoints 51 IL# PE#QQR 51 EFAPROXYN 51 T Pred 51 vidofludimus 51 Ozarelix 51 evaluating T DM1 51 relapsed refractory multiple myeloma 51 ZYBRESTAT fosbretabulin 51 T DM1 51 PS# [001] 51 Phase 2b randomized 51 COPERNICUS 51 denufosol 51 ABCSG 51 PRECISE trial 51 Phase 1b clinical 51 subgroup analyzes 51 FOLPI 51 pharmacodynamic 51 ENDEAVOR IV 51 Cloretazine R VNP#M 51 ACR# ACR# 51 Serious adverse reactions 51 CAMMS# 51 IV RSD# 51 LymphoStat B belimumab 51 tolevamer 51 deforolimus 51 CLIRS 51 double blinded placebo 51 pharmacodynamic effects 51 Plicera 51 Phase III Clinical Trials 51 relapsing remitting multiple sclerosis 51 ALISTA 51 RDEA# 51 Nasdaq PGNX today 51 ACCORD Lipid 51 Phase 2b Clinical Trial 51 MoxDuo IR 51 Phase 1b dose escalation 51 refractory AML 51 AZILECT R 51 dose escalation phase 50 IIa trial 50 ADAGIO study 50 Raptiva ® 50 Phase 2b 50 Dose Escalation 50 undetectable HBV DNA 50 TLR Timberline 50 MILAN TEN Tenaris 50 label multicenter randomized 50 randomized multicenter Phase III 50 randomized Phase IIb 50 prospective randomized controlled 50 APEX PD 50 CaPre TM 50 abysmal Shaiken 50 MEND CABG II 50 fostamatinib 50 randomized Phase 50 dose cohort 50 sapacitabine 50 Relapsed Multiple Myeloma 50 IMGN# 50 initiated Phase Ib 50 IRX 2 50 TAXUS ATLAS 50 viral kinetics 50 Phase #/#a trial 50 specified secondary endpoints 50 Primary endpoints 50 Marqibo 50 remission CR 50 Secondary endpoints 50 OAB overactive bladder 50 Ventavis 50 multicenter randomized controlled 50 recurrent glioblastoma 50 multicenter Phase II 50 Targretin capsules 50 Genz # 50 Phase III 50 docetaxel Taxotere R 50 Ophena 50 AVERROES 50 prospective multicenter randomized 50 NEVO RES 50 Anturol TM 50 EndoTAG TM -1 50 Diabetic Macular Edema 50 bicifadine 50 Proxinium TM 50 TMC# [002] 50 nab paclitaxel 50 alicaforsen enema 50 registrational Phase 50 diarrhea predominant irritable 50 Clolar ® 50 APTIMA HPV assay 50 perifosine KRX 50 phase IIb trial 50 FOLOTYN ® 50 HuMax CD4 50 TG MV 50 trastuzumab DM1 50 recurrent metastatic ovarian cancer 50 QLT# 50 visilizumab 50 platinum refractory 50 ORMD 50 Second Pivotal Phase 50 immunotherapeutic agent 50 vicriviroc 50 AEG# 50 PEGINTRON TM 50 Tarceva TM 50 Matrix Phase 2b 50 dextromethorphan quinidine 50 Subgroup analysis 50 hormone refractory prostate cancer 50 WDD# 50 PDX pralatrexate 50 tesetaxel 50 SPIRIT IV 50 T SPOT.TB test 50 EXPLORE Xa 50 dosing cohort 50 confirmatory Phase 3 50 Dacogen injection 50 microplasmin 50 Q4 LY 50 icatibant 50 MKC# MT 50 ADVEXIN efficacy 50 NSABP C 50 celgosivir 50 custirsen 50 sonographic findings 50 brivaracetam 50 sorafenib tablets 50 ruxolitinib 50 sodium glucose cotransporter 50 Pirfenidone 50 generation URAT1 inhibitor 50 MEK inhibitor RDEA# 50 PRX # 50 RSD# iv 50 investigational monoclonal antibody 50 ORACLE MS 50 comparing alemtuzumab 50 MIVI TRUST 50 Multicenter Phase 50 randomized controlled clinical 50 EXPAREL ™ 50 AIR CF2 50 Combination REOLYSIN R 50 evaluating Vectibix 49 Randomized Clinical Trial 49 Zerenex 49 metastatic colorectal cancer 49 Aryplase 49 Nasdaq ISTA 49 IIa clinical 49 LibiGel Phase III 49 TACI Ig 49 multicenter clinical 49 placebo controlled dose escalation 49 ZYBRESTAT 49 Clinical Trial Results 49 TLK# 49 mapatumumab 49 MLN# 49 Phase IIa 49 SinuNase TM 49 ancrod 49 ozarelix 49 antiviral efficacy 49 JAK1 49 preclinical pharmacokinetic 49 ADVANCE PD 49 Taxotere ® 49 aclidinium bromide 49 Phase III clinical 49 Xeloda ® 49 vandetanib 49 randomized multicenter 49 metastatic hormone refractory 49 Secondary efficacy endpoints 49 PARTNER Trial 49 PFO migraine 49 serum clusterin levels 49 Immunogenicity 49 APEX AMI trial 49 Nasdaq MAPP 49 tolerability 49 Serdaxin 49 TSX VENTURE OGR 49 plasma pharmacokinetics 49 Phase IIIb 49 nitazoxanide 49 phase Ib clinical 49 ORENCIA ® 49 pediatric glioma 49 Veronate 49 Medullary Thyroid Cancer 49 pivotal Phase III 49 AzaSite Plus 49 placebo controlled Phase III 49 neratinib 49 pseudobulbar affect PBA 49 fosbretabulin 49 NP2 Enkephalin 49 DNAWitness Y 49 NYSE Amex ANV 49 MIVI III 49 Chemophase 49 TELINTRA 49 Meta analyzes 49 PROVENGE sipuleucel T 49 Archexin 49 AEGR 49 TMC# C# 49 Testosterone MDTS ® 49 Anturol 49 TTF Therapy 49 Tesetaxel 49 Phase #b/#a trial 49 Bicifadine 49 preclinically 49 Histologic 49 CLIRS trial 49 peginesatide 49 topical INCB# 49 prospective randomized placebo 49 evaluating bafetinib 49 compound INCB# 49 multicenter phase 49 lomitapide 49 investigational pan BCR 49 Allovectin 7 ® 49 estrogen receptor ER 49 PROactive study 49 perifosine 49 aflibercept 49 GRN#L 49 LEP ETU 49 pegloticase 49 pharmacokinetic 49 humanized anti 49 Ostarine 49 budesonide MMX 49 Genasense ® 49 initiate multicenter 49 leading oral taxane 49 Telik Announces 49 Fibrillex TM 49 Flamel Technologies NASDAQ FLML 49 PLCO trial 49 Phase III confirmatory 48 HCD# [002] 48 Daclizumab 48 attached unaudited condensed 48 Locteron ® 48 PROMACTA 48 rALLy clinical trial 48 Inc. Nasdaq BCRX 48 INSPIRE Trial Phase III 48 Phase IIb 48 NCCTG N# 48 Metastatic Renal Cell Carcinoma 48 antibody titer 48 picoplatin 48 Solorel TM 48 Genta Incorporated OTCBB 48 belinostat 48 TABLE #.OS -#/# parent 48 HRPC 48 ALSYMPCA 48 opioid induced bowel dysfunction 48 trastuzumab Herceptin 48 Phase III pivotal 48 EGS# 48 VTEM airborne surveys 48 HCV antibody 48 PROSTVAC VF 48 Denufosol 48 Abcourt Barvue project 48 EVIZON 48 SCH # 48 Annamycin 48 Viramidine 48 Phase IIb trial 48 multicenter multinational 48 placebo controlled studies 48 PSN# [002] 48 Edge STudy 48 AZILECT ® 48 2 methoxyestradiol 48 AeroLEF TM 48 mGluR5 negative 48 Initiate Phase 48 Hyphanox 48 Active Ulcerative Colitis 48 Genasense oblimersen sodium Injection 48 LibiGel testosterone gel 48 hormone receptor negative 48 VADT 48 BiTE R 48 dose escalation study 48 CCR5 receptor antagonist 48 interferon gamma 1b 48 Allovectin 7 R 48 carfilzomib 48 completely resected 48 Phase IIa trials 48 NUVIGIL 48 rALLy trial 48 phase IIb III 48 ostarine 48 evaluable patients 48 ponatinib 48 evaluating carfilzomib 48 KRN# 48 Wisconsin Sleep Cohort 48 oral deforolimus 48 Phase IIb Trial 48 RIO Lipids 48 seliciclib CYC# 48 IMPROVE HF 48 TORISEL 48 Nasdaq ONXX today 48 HoFH 48 II Clinical Trial 48 Phase #b/#a clinical 48 Panzem R NCD 48 PROPEL trial 48 Achieves Primary Endpoint 48 PEARL HF 48 SILENOR TM 48 NYSE CHT Chunghwa 48 eculizumab 48 torezolid phosphate 48 NSABP B 48 Nasdaq ALKS 48 OPAXIO 48 PEG Interferon lambda 48 castrate resistant prostate cancer 48 investigational humanized monoclonal antibody 48 JAK inhibitor 48 Phase IIa clinical trials 48 Preclinical Study 48 AMWO 48 double blinded randomized 48 zanolimumab 48 Corlux 48 Tesmilifene 48 LymphoStat B TM 48 refractory chronic lymphocytic 48 IMC #B 48 blinded randomized 48 PANVAC VF 48 APPRAISE 48 NASDAQ CXSP announced 48 MADIT CRT trial 48 Sensitivity analyzes 48 AIR CF1 48 preclinical efficacy 48 trial evaluating PRX# 48 Serada 48 Meets Primary Endpoint 48 EOquin 48 catheter occlusion 48 ofatumumab 48 isavuconazole 48 UroVysion 48 Study Showed 48 sNDA submission 48 HRQL 47 ospemifene 47 relapsed multiple myeloma 47 Pivotal Phase II 47 geochemical assay 47 recurrent malignant glioma 47 Azixa 47 REVLIMID lenalidomide 47 Alzhemed 47 Phase III metastatic melanoma 47 GEM OS1 47 avanafil 47 pivotal bioequivalence 47 Wrestling Wrap Up 47 Pooled Analysis 47 Newly Diagnosed Multiple Myeloma 47 Randomised 47 CRx 47 acyclovir Lauriad ® 47 Arqule Inc ARQL 47 Anti Tumor Activity 47 R roscovitine CDK cyclin 47 seismic amplitude anomalies 47 evaluating Xcytrin 47 SinuNase 47 Inc. NASDAQ SNUS 47 IDX# 47 ENDEAVOR IV clinical 47 confirmatory Phase III 47 DCE MRI 47 Phase III AFFIRM 47 Randomized Controlled 47 Serdaxin ® 47 Troxatyl 47 unaudited consolidated balance sheets 47 Mineralized intercepts 47 randomized multicentre 47 RE SURGE 47 meta regression 47 trastuzumab Herceptin R 47 vinorelbine 47 AGI Alamos 47 urine cytology 47 my3KG 47 PI3K/Akt pathway inhibitor 47 dosing regimens 47 IOC reanalyzed 47 #.# perdiluted 47 Double Blind Placebo 47 Sangamo BioSciences Announces 47 Randomized Double Blind 47 Taxotere R 47 Inc. Nasdaq OPTR 47 Exherin TM 47 ENDEAVOR clinical 47 AZX# 47 Randomized controlled 47 zalutumumab 47 Æterna Zentaris 47 Phase III Pivotal 47 FOLOTYN 47 Iranian delegate Abolfazl 47 Randomized Phase III 47 FIRST NORTH PXXS 47 Phase Ib IIa 47 dose regimens 47 placebo controlled randomized 47 metastatic CRPC 47 PF # [001] 47 evaluating satraplatin 47 Perifosine 47 Phase III randomized controlled 47 LUMINATE 47 Repligen Corporation NASDAQ RGEN 47 selenium supplementation 47 Salix Pharmaceuticals Announces 47 OBPM 47 Alpharadin 47 cancer neuroendocrine tumor 47 BCIRG 47 AirBoss Announces 47 inferred resource calculation 47 evaluating satraplatin plus 47 virological response 47 treatment naive genotype 47 thorough QT 47 GATTEX ® 47 bevirimat Study 47 VP# [004] 47 acyclovir Lauriad R 47 EMPOWER ™ 47 Clolar 47 RIBBON 47 PROTECT AF 47 BioSante Pharmaceuticals Reports 47 Nasdaq OPTR 47 Late Breaker 47 Inc. NASDAQ NBIX 47 evaluating RDEA# 47 varespladib 47 Stent Restenosis 47 rNAPc2 47 LEVADEX 47 sunitinib malate 47 cutaneous T cell 47 AP# [003] 47 APTIMA HPV 47 metastatic castrate resistant 47 RC2 NASDAQ RCRC 47 randomized placebo controlled 47 valopicitabine 47 pharmacodynamics 47 treatment naïve genotype 47 unblinded 47 ofatumumab HuMax CD# 47 Pharmacodynamic 47 Perifosine KRX 47 APF# 47 here http:/www.mysmartrend.com/research/ 47 methylnaltrexone 47 First Patient Enrolled 47 satraplatin Phase 47 radiation sensitizer 47 PRNewswire FirstCall Genta Incorporated 47 Grouped Hockey 47 Microplasmin 47 Hormone receptor 47 caustic fusion diamond 47 TOLAMBA 47 LibiGel ® 47 mipomersen 47 unblind 47 QNEXA 47 placebo controlled 47 Idenix Pharmaceuticals Reports 47 CAPRIE 47 HspE7 47 novel histone deacetylase 47 Phase 2b Study 47 TSX PLS 47 maribavir 47 MoxDuo ® IR 47 anticancer compound 47 #m@#.#g t [001] 46 ICON7 46 cabozantinib 46 antibody MAb 46 continuingoperations 46 rindopepimut 46 multicenter Phase III 46 blinatumomab 46 HGS# 46 pressure nCPAP 46 FavId 46 AACR Frontiers 46 Ofatumumab 46 ELND# 46 Inc. Nasdaq EXEL 46 Maximum Tolerated Dose 46 fidaxomicin Phase 3 46 confirmatory Phase 46 Statistically Significant Improvement 46 Company TSX ANV 46 Onalta ™ 46 Cluuz search 46 Phase #b/#a 46 Ansel interpreted 46 controlled multicenter 46 lorvotuzumab mertansine 46 MIST II 46 Multicenter Automatic Defibrillator Implantation 46 talactoferrin 46 Halotron revenues 46 Phase IIb III 46 multicenter randomized 46 ADMIRE HF 46 Negative Symptom Scale PANSS 46 OvaRex ® MAb 46 normalized FFO 46 LEUKINE 46 chromium picolinate supplementation 46 Phase III psoriasis 46 nonclinical studies 46 animal xenograft models 46 European Sepsis Trial 46 bronchial lavage 46 painful diabetic neuropathy 46 controlled multicenter Phase 46 Summary CONDENSED CONSOLIDATED 46 PRNewswire FirstCall ISTA Pharmaceuticals 46 label multicenter 46 registrational 46 Efficacy Results 46 NSCLC 46 Phase 2b clinical trials 46 refractory CLL 46 IGXT IntelGenx today 46 panitumumab 46 holes #WR# 46 RE MODEL 46 LSE YAU 46 Completes Patient Enrollment 46 Inc. Nasdaq TELK 46 Q#/FY# 46 Cystatin C 46 PRECISE Trial 46 Nexavar ® 46 Dr. Fahar Merchant 46 CRMD# 46 Cimzia ® 46 Relapsing Remitting Multiple Sclerosis 46 ZK EPO 46 Techni lab 46 Nasdaq ALTH 46 teduglutide 46 GLP toxicology studies 46 Zybrestat 46 investigational compounds 46 duplex ultrasonography 46 lumiliximab 46 Clinical Diagnostics segment 46 oral taxane 46 Zenvia 46 Ameris Bancorp Reports 46 Aromatase Inhibitors 46 DAVANAT R exhibits 46 spokesman Naoya Narita 46 LBH# 46 Histopathologic 46 ATAC Arimidex Tamoxifen Alone 46 severe hypercholesterolemia 46 Hedgehog antagonist 46 Tumor Response 46 Simulations Plus Reports 46 TAXUS Element Stent System 46 CALERIE 46 Panzem R 46 initiate Phase 2b 46 Nasdaq VRTX 46 THALOMID 46 Dual Opioid 46 mean ± SEM 46 Phase III randomized 46 LE SN# 46 Norcraft Companies LP Norcraft 46 iroxanadine 46 Cloretazine 46 Recurrence Score 46 NASDAQ SLXP today 46 ELISpot 46 Omacetaxine 46 CA4P 46 thermal coefficient NTC 46 Serious Adverse Events 46 PrevOnco ™ 46 refractory metastatic colorectal cancer 46 single ascending dose 45 Controlled Trial 45 Cochrane reviewers 45 StemEx 45 Cloretazine ® 45 AVGCF Avion 45 Phase II 45 Hsp# Inhibitor 45 Significant mineralized intercepts 45 Onrigin 45 Cotara 45 trodusquemine 45 romidepsin 45 TOFUTTI Announces 45 Renal Cell Carcinoma RCC 45 NYSE MIM MID 45 Placebo Controlled Trial 45 Plus Ribavirin 45 SCHEDULED TO PREMIERE 45 statin monotherapy 45 Trial Evaluating 45 resutls 45 Inc. NASDAQ MIPI 45 Board INTZ Intrusion 45 results 45 pralatrexate 45 Supplemental Schedules 45 Relapsing Multiple Sclerosis 45 Study GL# 45 Phase III trials 45 NYSE Euronext PHARM 45 PEGylated interferon beta 1a 45 Kaplan Meier analysis 45 unblinding 45 brain metastases originating 45 Gastrointestinal Stromal Tumors 45 histamine dihydrochloride 45 VIAject 45 Phase IIb Clinical Trial 45 abstracts summarizing 45 Clonicel 45 intravascular ultrasonography 45 microdiamond results 45 BHEM surveys 45 Fx #A 45 dirucotide MBP# 45 EMBLEM ™ 45 prospective multicenter 45 BRAF V# mutation 45 Patient Outcomes 45 dasatinib Sprycel ® 45 PDP MLR 45 monotherapy 45 ADCS CGIC 45 PHX# 45 Sirolimus Eluting 45 Tanespimycin 45 Ambulatory Blood Pressure 45 TSX COM 45 lintuzumab SGN 45 Carotid Revascularization Endarterectomy vs.